Trial Profile
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs T cell replacement therapy TH 9402 (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Kiadis Pharma
- 06 Nov 2019 Results of pooled post-hoc analysis assesing overall survival by using data from three studies including this study released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Nov 2019 According to a Kiadis Pharma media release, new ATIR101 data will be discussed in an oral presentation exploring the effect of a single infusion of ATIR101 on survival outcomes in patients with blood cancer who underwent T-cell depleted haploidentical-hematopoietic stem cell transplantation (haplo-HSCT) from a pooled analysis of two Phase II trials (CR-AIR-007, NCT01794299; CR-AIR-008, NCT02500550) at the 59th Annual Meeting of the American Society of Hematology (ASH).
- 28 May 2019 This trial has been completed in Croatia, according to European Clinical Trials Database.